Who are HL-040XC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Immune Checkpoint Inhibitors, Cisplatin / Carboplatin，Gemcitabine，Cindilimab, HL301(Experimental), Reference0912, Praga formulation, SPARC1104 modified dose regimen I.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hl-040xc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

HL-040XC — Competitive Intelligence Brief

HL-040XC (HL-040XC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody; immune checkpoint inhibitor. Area: Oncology.

phase 3 Bispecific antibody; immune checkpoint inhibitor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HL-040XC (HL-040XC) — HanAll BioPharma Co., Ltd.. HL-040XC is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HL-040XC TARGET	HL-040XC	HanAll BioPharma Co., Ltd.	phase 3	Bispecific antibody; immune checkpoint inhibitor
Immune Checkpoint Inhibitors	Immune Checkpoint Inhibitors	The Central Hospital of Lishui City	marketed	Immune checkpoint inhibitor
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
HL301(Experimental)	HL301(Experimental)	Hanlim Pharm. Co., Ltd.	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
Reference0912	Reference0912	Sun Pharma Advanced Research Company Limited	phase 3	Immune checkpoint inhibitor	PD-1
Praga formulation	Praga formulation	EMS	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
SPARC1104 modified dose regimen I	SPARC1104 modified dose regimen I	Sun Pharma Advanced Research Company Limited	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody; immune checkpoint inhibitor class)

HanAll BioPharma Co., Ltd. · 1 drug in this class
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HL-040XC — Competitive Intelligence Brief. https://druglandscape.com/ci/hl-040xc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab